Double Delight For Novartis At The CHMP
Backing For MS Drug Mayzent And Isturisa For Cushing's
Novartis has received two positive opinions in Europe, the most important being for Mayzent, its active secondary progressive multiple sclerosis drug which is key to the company's ambitions for growth in the neurology space.
